<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146535</url>
  </required_header>
  <id_info>
    <org_study_id>QCR09025</org_study_id>
    <nct_id>NCT01146535</nct_id>
  </id_info>
  <brief_title>Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment</brief_title>
  <official_title>Pilot Study of Interferon Alpha Lozenges Plus Oseltamivir in the Treatment of Influenza A Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amarillo Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CytoPharm, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amarillo Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and effect of interferon-alpha lozenges when used in
      combination with oseltamivir (Tamiflu) to treat influenza.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of fever and flu symptoms</measure>
    <time_frame>Days 1-5</time_frame>
    <description>Time to resolution of influenza symptoms defined as all flu symptoms scored as &lt;=1 and change in viral load (RT-PCR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Day 3 and Day 6</time_frame>
    <description>Proportion of clinical responders on Day 3 and Day 6: defined as no fever (oral temperature &lt; 38 °C and no subjective fever) AND resolution of influenza illness (all flu symptoms and interference scored as ≤ 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of poor responders</measure>
    <time_frame>Day 3 and Day 6</time_frame>
    <description>Proportion of poor responders on both Day 3 and Day 6: defined as subjects with fever (oral temperature ≥ 38 °C or any record of subjective fever) OR unresolved influenza illness (1 or more flu symptoms/interferences scored as &gt; 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever</measure>
    <time_frame>Days 1-5</time_frame>
    <description>Time to bring down a fever (oral temperature &lt; 38 °C and no subjective fever) and time to return to afebrile state (oral temperature ≤ 37.2 °C and no subjective fever).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of influenza illness</measure>
    <time_frame>Days 1-5</time_frame>
    <description>Time to resolution of influenza illness (all flu symptoms and interference scored as ≤ 1) as reported by the subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom improvement</measure>
    <time_frame>Days 1-5</time_frame>
    <description>Improvement of influenza symptoms and level of interference of disease during treatment period as reported by the subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OTC medication usage</measure>
    <time_frame>Days 1-5</time_frame>
    <description>Proportion of use of the OTC medication for fever or influenza symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician visits</measure>
    <time_frame>Days 6-10</time_frame>
    <description>Rate of requirement for additional physician visits within 5 days treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>Days 1-28</time_frame>
    <description>Rate of treatment failure including hospitalization due to disease progression prior to Day 29.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Influenza A Virus Infection</condition>
  <arm_group>
    <arm_group_label>Interferon-alpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon-alpha
150 IU lozenges bid for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maltose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maltose
200 mg maltose lozenges bid for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-alpha</intervention_name>
    <description>150 IU lozenges bid for 5 days</description>
    <arm_group_label>Interferon-alpha</arm_group_label>
    <other_name>IFN lozenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>75 mg capsules bid for 5 days</description>
    <arm_group_label>Interferon-alpha</arm_group_label>
    <arm_group_label>maltose</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>maltose</intervention_name>
    <description>200 mg maltose lozenges bid for 5 days</description>
    <arm_group_label>maltose</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  fever &gt;=38C

          -  one or more respiratory symptoms (e.g. cough, rhinorrhea or sore throat) plus one or
             more constitutional symptoms (e.g. chills, headache, malaise and myalgias)of &lt; 48
             hours' duration

          -  body weight &gt; 40 kg

          -  positive for influenza A (nasal swab rapid test)

        Exclusion Criteria:

          -  pregnancy/lactation

          -  history of depression or psychiatric disorders

          -  history of conditions that could complicate flu infection, such as chronic pulmonary,
             cardiac, renal, or metabolic disorders

          -  use of immunosuppressive therapy

          -  HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation, LinKou Branch</name>
      <address>
        <city>Guishan</city>
        <state>Taoyuan County</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <state>Zuoying District</state>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Show-Chwan Memorial Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>800</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taiwan Municipal Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>701</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>August 19, 2013</last_update_submitted>
  <last_update_submitted_qc>August 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interferon-alpha</keyword>
  <keyword>oseltamivir</keyword>
  <keyword>drug therapy, combination</keyword>
  <keyword>influenza</keyword>
  <keyword>therapies, investigational</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

